Israel’s Pharma Two B raises $30 mln for trial of Parkinson’s treatment – Reuters

JERUSALEM, Feb 27 (Reuters) -

* Israel-based Pharma Two B, which is developing treatments for Parkinsons disease, said on Monday it completed a third round of financing for $30 million.

* The company said the funds will be used to complete the final phase III clinical trial needed to register P2B001, its lead combination product for the treatment of Parkinsons disease.

* The financing was led by Israel Biotech Fund and included biotech investors aMoon and JVC, as well as current investor, Chicago-based JK&B Capital.

* Pharma Two B said P2B001 could potentially help in the early stage of the disease and also be an add-on to Levodopa, which is today a main drug choice. (Reporting by Ari Rabinovitch)

* Bayer to publish more details on Wednesday (Adds details on stake, background on Monsanto financing)

WASHINGTON, Feb 28 A Republican effort to repeal and replace Obamacare encountered resistance on Tuesday from party conservatives who said draft legislation emerging in the U.S. House of Representatives would not reduce the cost of healthcare.

* Reports positive results in its phase III clinical trial with gp-ASIT+ for grass pollen induced allergic rhinitis

Link:
Israel's Pharma Two B raises $30 mln for trial of Parkinson's treatment - Reuters